XML 74 R62.htm IDEA: XBRL DOCUMENT
v3.21.1

Commitments and Contingencies (Details) |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 16 Months Ended | 18 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 11, 2020 | Oct. 02, 2019 | Sep. 11, 2019 patent | Nov. 30, 2018 patent | Feb. 22, 2018 patent | Mar. 24, 2015 patent | Feb. 11, 2015 patent | Oct. 31, 2019 case | Mar. 31, 2021 lawsuit patent case state | Jun. 30, 2020 patent | Dec. 31, 2018 patent | Sep. 30, 2017 patent | Apr. 30, 2017 patent lawsuit
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
Period that gives the Company a 30-month stay of FDA approval while the parties have an opportunity to litigate |  |  |  |  | 45 days |  |  |  |  |  |  |  |
Additional patent listed |  |  |  |  |  |  |  |  |  | 4 |  |  |
Xtampza ER |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
Number of total patent |  |  |  |  |  |  |  |  | 19 |  |  |  |
Xtampza ER Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents listed in FDA Orange Book |  |  |  |  |  |  | 11 |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  |  |  | 30 months |  |  |  |  |  |
Number of patents allegedly infringed |  |  |  |  |  |  | 5 |  |  |  |  | 2 | 2
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  |  |  |  |  |  | 2
PTAB duration for issuing decision |  | 1 year |  |  |  |  |  |  |  |  |  |  |
Statutory period of proceedings | 18 months |  |  |  |  |  |  |  |  |  |  |  |
Xtampza ER Litigation | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
PTAB extended duration for issuing decision |  | 6 months |  |  |  |  |  |  |  |  |  |  |
Xtampza ER Litigation, District of Delaware |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  |  | 30 months |  |  |  |  |  |  |
Number of patents allegedly infringed |  |  |  |  |  | 3 |  |  |  |  |  |  |
Xtampza ER Litigation, District of Massachusetts |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  |  | 30 months |  |  |  |  |  |  |
Number of patents found not infringed |  |  |  |  |  | 3 |  |  |  |  |  |  |
Teva Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents listed in FDA Orange Book |  |  |  |  | 12 |  |  |  | 19 |  |  |  |
Number of Orange Book patents asserted to have been infringed |  |  |  | 2 |  |  |  |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  | 30 months |  |  |  |  |  |  |  |
Number of patents found not infringed |  |  |  |  | 11 |  |  |  |  |  |  |  |
Number of terms or sets of terms addressed |  |  | 2 |  |  |  |  |  |  |  |  |  |
Number of terms or sets of terms in dispute |  |  | 6 |  |  |  |  |  |  |  |  |  |
Additional patent listed |  |  |  |  |  |  |  |  |  |  | 2 |  |
Opioid Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  |  | 6 |  |  |  |
Number of lawsuits designated as representative cases | lawsuit |  |  |  |  |  |  |  |  | 0 |  |  |  |
Number of lawsuits designated as Track One case | lawsuit |  |  |  |  |  |  |  |  | 0 |  |  |  |
Multi-District Litigation (MDL) |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |
Number of states filed cases | state |  |  |  |  |  |  |  |  | 3 |  |  |  |
Total number of cases brought primarily by states, cities, counties, and other local entities | case |  |  |  |  |  |  |  |  | 2,000 |  |  |  |
Number of lawsuits filed |  |  |  |  |  |  |  | 2 | 21 |  |  |  |
Number of lawsuits currently stayed | case |  |  |  |  |  |  |  |  | 8 |  |  |  |
Number of lawsuits settled | lawsuit |  |  |  |  |  |  |  |  | 13 |  |  |  |
Number of lawsuits dismissed | lawsuit |  |  |  |  |  |  |  |  | 3 |  |  |  |

X
- Definition Initial duration for issuing its decision by PTAB. + References No definition available. + Details
Name: | coll_DurationForDecisionIssue
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extended period for issuing its decision by PTAB. + References No definition available. + Details
Name: | coll_ExtendedDurationForDecisionIssue
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's Orange Book patents that the entity has allegedly infringed. + References No definition available. + Details
Name: | coll_LossContingencyOrangeBookPatentsAllegedlyInfringedNumber
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the stay period before the Federal Drug Administration (FDA) can issue final approval unless the stay is terminated. + References No definition available. + Details
Name: | coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional patents listed during the period. + References No definition available. + Details
Name: | coll_NumberOfAdditionalPatentsListed
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition This represents information pertaining to number of lawsuits currently stayed. + References No definition available. + Details
Name: | coll_NumberOfLawsuitsCurrentlyStayed
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of lawsuits designated as representative cases. + References No definition available. + Details
Name: | coll_NumberOfLawsuitsDesignatedAsRepresentativeCases
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of lawsuits designated as Track One case. + References No definition available. + Details
Name: | coll_NumberOfLawsuitsDesignatedTrackOneCase
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of cases brought primarily by states, cities, counties, and other local entities. + References No definition available. + Details
Name: | coll_NumberOfLawsuitsFiled
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patents listed in FDA Orange Book + References No definition available. + Details
Name: | coll_NumberOfPatentsListedInFdaOrangeBook
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of states filed cases. + References No definition available. + Details
Name: | coll_NumberOfStatesFiledCases
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of terms or sets of terms, that are in dispute, are addressed in a Report and Recommendation. + References No definition available. + Details
Name: | coll_NumberOfTermsOrSetsOfTermsAddressed
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of terms or sets of terms that are in dispute. + References No definition available. + Details
Name: | coll_NumberOfTermsOrSetsOfTermsInDispute
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of total patents listed during the period. + References No definition available. + Details
Name: | coll_NumberOfTotalPatentsListed
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period that gives the Company a 30-month stay of FDA approval while the parties have an opportunity to litigate. + References No definition available. + Details
Name: | coll_PeriodStayOfApprovalAndOpportunityToLitigate
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Statutory period of proceedings. + References No definition available. + Details
Name: | coll_StatutoryPeriodOfProceedings
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of claims dismissed. + References No definition available. + Details
Name: | us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of claims settled and dismissed during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyClaimsSettledAndDismissedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total number of new claims filed pertaining to a loss contingency during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity was found not to have infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsFoundNotInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=coll_XtampzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_TevaLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_OpioidLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_MultiDistrictLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |